John R. Wetterau
Research Subjects
John R. Wetterau has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Beverly Ricci
1 shared publicationChing-Hsuen Chu
1 shared publication- Christa M. Musial
Bristol Myers Squibb
1 shared publication Cynthia Arbeeny
1 shared publicationDavid A. Gordon
1 shared publicationDavid R. Magnin
1 shared publication
Latest Publications
- 23 October 1998
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 282 (5389) , 751-754
An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits
Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B–containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9 ) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound 9 , or derivatives thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.
- 23 October 1998
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 282 (5389) , 751-754
An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits
Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B–containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9 ) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound 9 , or derivatives thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.